Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphoea by severity and identify...

Area of Science:

• Dermatology
• Rheumatology
• Clinical Trials

Background:

• Validated scoring measures are crucial for advancing morphoea clinical trials.
• The Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) is established for quantifying morphoea activity and damage.
• Prior research confirms the validity and reliability of the LoSCAT.

Purpose of the Study:

• To determine the clinical significance of LoSCAT scores in morphoea.
• To identify score changes in the LoSCAT that correlate with clinically meaningful disease alterations.
• To establish objective criteria for assessing morphoea severity and treatment response.

Main Methods:

• A prospective study involved 120 participants from the Morphea in Adults and Children (MAC) cohort.
• Physician assessments of disease severity and improvement were recorded at each visit.
• Receiver operating characteristic analysis was used to define score thresholds for disease severity and change.

Main Results:

• LoSCAT Activity Index (LoSAI) and Physician's Global Assessment of Activity (PGA-A) scores were correlated with mild, moderate, and severe activity levels.
• LoSCAT Damage Index (LoSDI) and Physician's Global Assessment of Damage (PGA-D) scores were correlated with mild, moderate, and severe damage levels.
• Specific score changes in LoSAI, PGA-A, and LoSDI were identified as indicators of clinically significant improvement or worsening.

Conclusions:

• The LoSCAT is effective in classifying morphoea disease severity into mild, moderate, and severe categories.
• The LoSCAT successfully identifies clinically significant improvements in morphoea disease activity.
• The LoSCAT's utility in detecting clinically significant changes in disease damage may be limited.